News & Updates

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

08 Feb 2022

REL-1017 (esmethadone), a novel N-methyl-D-aspartate receptor channel blocker, demonstrates favourable safety, tolerability, and pharmacokinetic profiles and appears to have rapid and sustained antidepressant effects relative to placebo in major depressive disorder patients with inadequate responses to antidepressant treatments, according to a recent study.

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

08 Feb 2022

Social unrest and pandemic take a toll on HK women’s mental health

07 Feb 2022 by

Exposure to social unrest and the coronavirus disease 2019 (COVID-19) pandemic may increase depressive and post-traumatic stress disorder (PTSD) symptoms among women in Hong Kong, according to a study by the Queen Mary Hospital and University of Hong Kong (HKU).

Social unrest and pandemic take a toll on HK women’s mental health

07 Feb 2022

Adjunctive ketamine safe, effective in alcohol use disorder

07 Feb 2022

Treatment with three infusions of ketamine is acceptable among patients with alcohol use disorder and results in more days of abstinence from alcohol at 6-month follow-up, a study has shown.

Adjunctive ketamine safe, effective in alcohol use disorder

07 Feb 2022

Anxiety during pregnancy speeds up genetic ageing in baby boys

07 Feb 2022 by

Prenatal maternal anxiety is correlated with markers of epigenetic age acceleration in male infants, irrespective of other genetic, socioeconomic, or obstetric risk factors, according to a recent study

Anxiety during pregnancy speeds up genetic ageing in baby boys

07 Feb 2022

Stanford neuromodulation therapy effective against treatment-resistant depression

06 Feb 2022

The Stanford neuromodulation therapy (SNT), a high-dose intermittent theta-burst stimulation (iTBS) protocol with functional-connectivity-guided targeting, demonstrates better efficacy than sham stimulation for treatment-resistant depression, according to the results of a double-blind, randomized controlled trial.

Stanford neuromodulation therapy effective against treatment-resistant depression

06 Feb 2022

Acupuncture bests pharmacotherapy for relieving depression, anxiety in FGID patients

05 Feb 2022

Acupuncture seems to be better than pharmacotherapy at relieving emotional symptoms in patients with functional gastrointestinal disorders (FGIDs), reports a recent meta-analysis.

Acupuncture bests pharmacotherapy for relieving depression, anxiety in FGID patients

05 Feb 2022

Depressive symptoms associated with endorsement of COVID-19 vaccine misinformation

04 Feb 2022 by

People with moderate or severe depressive symptoms are more likely to endorse misinformation about coronavirus disease 2019 (COVID-19) vaccines, and those who embrace vaccine misinformation are half as likely to be vaccinated, a study in the US has shown.

Depressive symptoms associated with endorsement of COVID-19 vaccine misinformation

04 Feb 2022

What predisposes schizophrenia patients to aggression?

31 Jan 2022 by

In schizophrenia patients with related psychoses, physical aggression seems to be higher among men, those with lower education, and those diagnosed at an older age, according to a recent Singapore study.

What predisposes schizophrenia patients to aggression?

31 Jan 2022

Serum selenium unrelated to depression, but supplementation could prove protective

30 Jan 2022

High selenium intake seems to exert a significant protective effect against postpartum depression, reports a recent meta-analysis. Selenium may be considered as a potential adjuvant therapy in patients with depression.

Serum selenium unrelated to depression, but supplementation could prove protective

30 Jan 2022

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing

26 Jan 2022

Obsessive-compulsive symptoms appear to frequently occur among schizophrenic patients receiving treatment with clozapine, and these symptoms exert a negative effect on the patients’ wellbeing, a study reports.

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing

26 Jan 2022

News & Updates

Filter by Specialty:

Specialty:

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

Social unrest and pandemic take a toll on HK women’s mental health

Social unrest and pandemic take a toll on HK women’s mental health

Adjunctive ketamine safe, effective in alcohol use disorder

Adjunctive ketamine safe, effective in alcohol use disorder

Anxiety during pregnancy speeds up genetic ageing in baby boys

Anxiety during pregnancy speeds up genetic ageing in baby boys

Stanford neuromodulation therapy effective against treatment-resistant depression

Stanford neuromodulation therapy effective against treatment-resistant depression

Acupuncture bests pharmacotherapy for relieving depression, anxiety in FGID patients

Acupuncture bests pharmacotherapy for relieving depression, anxiety in FGID patients

Depressive symptoms associated with endorsement of COVID-19 vaccine misinformation

Depressive symptoms associated with endorsement of COVID-19 vaccine misinformation

What predisposes schizophrenia patients to aggression?

What predisposes schizophrenia patients to aggression?

Serum selenium unrelated to depression, but supplementation could prove protective

Serum selenium unrelated to depression, but supplementation could prove protective

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing